STOCK TITAN

Minerva Neurosciences Inc - NERV STOCK NEWS

Welcome to our dedicated news page for Minerva Neurosciences (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Minerva Neurosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Minerva Neurosciences's position in the market.

Rhea-AI Summary
Minerva Neurosciences, Inc. receives a Complete Response Letter from the FDA for roluperidone, citing clinical deficiencies in the NDA submission for treating negative symptoms in schizophrenia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.82%
Tags
none
-
Rhea-AI Summary
Minerva Neurosciences, Inc. (NERV) reports positive business updates and financial results for Q4 and year-end 2023. FDA accepted NDA for roluperidone, a potential breakthrough medication for negative symptoms of schizophrenia. R&D expenses increased due to FDA review, while G&A expenses fluctuated. Net loss improved slightly, and cash position strengthened.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.61%
Tags
-
Rhea-AI Summary
Minerva Neurosciences, Inc. reports business updates, focusing on the FDA review of its New Drug Application for roluperidone to treat negative symptoms of schizophrenia, with R&D expenses increasing and a net loss of $7.8 million for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
-
Rhea-AI Summary
Minerva Neurosciences announces private investment in public equity (PIPE) financing of approximately $20 million to support the development and commercialization of roluperidone for the treatment of negative symptoms in schizophrenia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
69.27%
Tags
none
-
Rhea-AI Summary
Minerva Neurosciences, Inc. reported business updates and financial results for Q1 2023. The company achieved a significant milestone with the FDA filing their New Drug Application for roluperidone, a treatment for negative symptoms of schizophrenia. The FDA has set a goal date of February 26, 2024 for approval. Minerva believes this drug has the potential to be the first approved treatment for these symptoms in the U.S. and could greatly impact patients' quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.42%
Tags
Rhea-AI Summary
Minerva Neurosciences announces FDA acceptance of NDA filing for roluperidone, with a goal date of February 26, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
Minerva Neurosciences Inc

Nasdaq:NERV

NERV Rankings

NERV Stock Data

17.76M
5.44M
22.26%
35.1%
0.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About NERV

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its